Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: J Addict Med. 2011 Mar;5(1):21–27. doi: 10.1097/ADM.0b013e3181d41ddb

TABLE 3.

Adoption and Implementation of Pharmacotherapies in Private Sector Specialty Addiction Treatment Facilities, 2007-2008

Program-Level Adoption Implementation
Full
sample of
programs

%		 % of
programs
with access to
physician(s)
%		 Number
of
adopting
programs
N		 % of eligible
clients receiving
medication in
adopting programs
Mean (SD)*
Psychiatric medications 54.5 70.7 188 70.1 (28.5)
Opioid treatment medications
 Methadone (detoxification) 8.1 10.5 28 55.4 (43.7)
 Methadone (maintenance) 7.8 10.2 27 41.3 (43.9)
 Buprenorphine (detoxification) 32.8 42.5 113 60.5 (38.9)
 Buprenorphine (maintenance) 20.9 27.1 72 37.3 (33.5)
 Tablet naltrexone 22.0 28.6 76 10.9 (21.2)
Alcohol treatment medications
 Disulfiram 23.8 30.8 82 8.1 (15.7)
 Tablet naltrexone 32.2 41.7 111 12.4 (16.0)
 Acamprosate 32.5 42.1 112 17.5 (17.2)
 Injectable naltrexone 15.9 20.7 55 **
*

Valid N varies by row and includes only those programs prescribing each medication.

**

Too few clients to calculate meaningful percentages. As of survey date, average program had delivered injectable naltrexone to 8 alcohol-dependent clients since its adoption.